Loading clinical trials...
Loading clinical trials...
Kinesia-D Phase II In-Clinic Continuous Assessment Study
The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.
Age
21 - No limit years
Sex
ALL
Healthy Volunteers
No
Johns Hopkins Medical Center
Baltimore, Maryland, United States
University of Rochester Medical Center
Rochester, New York, United States
Start Date
July 1, 2014
Primary Completion Date
December 1, 2014
Completion Date
December 1, 2014
Last Updated
January 12, 2016
14
ACTUAL participants
Lead Sponsor
Great Lakes NeuroTechnologies Inc.
Collaborators
NCT07310264
NCT02119611
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07216976